Home Newsfeeds Histogen Granted European Patent Titled ‘EXTRACELLULAR MATRIX COMPOSITIONS’

Histogen Granted European Patent Titled ‘EXTRACELLULAR MATRIX COMPOSITIONS’

https://register.epo.org/application?number=EP09706122

byBenzinga Newsdesk

August 19, 2022

1 minute read

https://register.epo.org/application?number=EP09706122

What’s Going On With Trump-Linked Phunware Stock Today?

By Adam Eckert

February 7, 10:38 AM

Phunware launched a $10 million public offering on Wednesday. The company said it plans to offer and sell 40 million shares of its common stock at a price of 25 cents per share. All of the shares are being offered by Phunware.

PHUN

Investor Optimism Improves Slightly Following Jobs Data; US Stocks Record Weekly Gains

By Avi Kapoor

June 10, 2:08 AM

The CNN Money Fear and Greed index showed a slight increase in the overall market sentiment, while the…

CVGW

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst

By Vandana Singh

September 6, 2:45 PM

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

BIIB

These Analysts Revise Price Targets On Sportradar Following Q4 Results

By Lisa Levin

March 16, 8:49 AM

Sportradar Group AG (NASDAQ: SRAD) reported fourth-quarter results. Sportradar reported fourth-quarter revenue of €206.3 million ($220.7 million), up 35% year-over-year. The company reported an adjusted EBITDA loss of $37.6 million, which was improved on a year-over-year basis.

SRAD

Histogen Granted European Patent Titled ‘EXTRACELLULAR MATRIX COMPOSITIONS’

Related Posts

What’s Going On With Trump-Linked Phunware Stock Today?

Investor Optimism Improves Slightly Following Jobs Data; US Stocks Record Weekly Gains

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst

These Analysts Revise Price Targets On Sportradar Following Q4 Results